实用医学杂志 ›› 2021, Vol. 37 ›› Issue (5): 569-573.doi: 10.3969/j.issn.1006⁃5725.2021.05.003

• 临床新进展 • 上一篇    下一篇

双膦酸盐治疗原发性骨质疏松症的研究进展

李奕玉 ,关雅心, 吴斌   

  1. 昆明医科大学第一附属医院内分泌一科(昆明 650032)

  • 出版日期:2021-03-10 发布日期:2021-03-10
  • 通讯作者: 吴斌 E⁃mail:wu.bin.kmu@qq.com
  • 基金资助:

    国家自然科学基金(编号:81660141);云南省卫生 科技计划项目(编号:2018NS0131)

Research progress in bisphosphonates for treatment of primary osteoporosis

LI Yiyu,GUAN Yaxin,WU Bin   

  1. Department of Endocrinology,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,China 

  • Online:2021-03-10 Published:2021-03-10
  • Contact: WU Bin E⁃mail:wu.bin.kmu@qq.com

摘要:

骨质疏松症是一种全身代谢性疾病,双膦酸盐已被证实在提高骨密度和降低骨折风险方面 有显著疗效,是目前临床上治疗骨质疏松症的一线药物。本文将从几种常见双膦酸盐的作用机制、临床 疗效、不良反应以及药物假期等方面展开综述,以期为临床用药选择提供参考。

关键词:

双膦酸盐, 骨质疏松症, 临床疗效, 不良反应, 药物假期

Abstract:

Osteoporosis is a systemic metabolic disease. Bisphosphonates are the first ⁃line drugs in the treatment of osteoporosis,which have been proved to have significant effects on improving bone density and reduc⁃ ing the risk of fracture. This article systematically reviewed the mechanism of action,clinical efficacy,adverse reactions and drug holiday of several bisphosphonates,which might provide useful information for future research.

Key words:

bisphosphonates, osteoporosis, clinical efficacy, adverse reactions, drug holiday